Paratek Pharmaceuticals — Transcept Pharmaceuticals — Investor Presentation (August 2010)
50 slides from Paratek Pharmaceuticals's investor presentation, Aug 3, 2010
Slide 1: Transcept Pharmaceuticals, Inc.
Exhibit 99.1 Transcept PHARMACEUTICALS, INC. A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience August 2010
Slide 2: Forward looking statements
Forward looking statements This slide deck contains forward-looking statements based upon current expectations within the meaning of the Private Securities Reform Act of 1995. Such statements involve risks and uncertainties. Actual results may differ significantly from that discussed in the forward-
Slide 3: Transcept Pharmaceuticals: company profile
Transcept Pharmaceuticals: company profile Public listing through reverse merger in Jan 2009 – Nasdaq:TSPT Intermezzo® (zolpidem tartrate sublingual tablet): lead product candidate U.S. primary care partnership with Purdue Pharma, psychiatry co-promote option Strong balance sheet: $83.1M of cash, ca
Slide 4: Transcept Pharmaceuticals: key corporate events
Transcept Pharmaceuticals: key corporate events Intermezzo®: Preclinical program and two Phase 3 studies completed: 2004-2008 Intermezzo® NDA submitted: September 2008 U.S. commercial partnership: Purdue, Intermezzo® primary care marketing and sales: July 2009 Intermezzo® Complete Response Letter re
Slide 5: Intermezzo®
Intermezzo® Proposed indication statement: Intermezzo® (zolpidem tartrate sublingual tablet) is indicated for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep
Slide 6: U.S. insomnia market
U.S. insomnia market: ~76 M insomnia prescriptions, March 2009-March 2010 Total Insomnia Prescriptions Total Annual Prescriptions (MAT millions) 0,10,20,30,40,50,60,70,80,90 Mar-06 May-06 Jul-06 Sep-06 Nov-06 Jan-07 Mar-07 May-07 Jul-07 Sep-07 Nov-07 Jan-08 Mar-08 May-08 Jul-08 Sep-08 Nov-08 Jan-09
Slide 7: Stanford Sleep Epidemiology Research Center: middle of the night awakening
Stanford Sleep Epidemiology Research Center: middle of the night awakening: #1 insomnia symptom Large scale population based sleep epidemiology study*, ~9,000 subjects over 4 years 35% report awakenings at least 3x per week >90% report awakenings persist more than six months Fewer than 25% of the mi
Slide 8: Intermezzo®: no product currently indicated for prn treatment of middle of the night awakening
Intermezzo®: no product currently indicated for prn treatment of middle of the night awakening Middle of the night awakenings typically did not occur every night, even in a more severely affected patient group* Commonly prescribed 7 to 8 hour sleep aids require bedtime prophylactic dosing before an
Slide 9: Intermezzo®: anticipated to be the first sleep aid for middle of the night awakening
Intermezzo®: anticipated to be the first sleep aid for use at the time of a middle of the night awakening Novel formulation Sublingual tablet dissolves in ~ 2 minutes pH drives zolpidem base, rapidly absorbed Low dose 72% lower dose than Ambien CR®, the most commonly prescribed insomnia brand Fast a
Slide 10: Intermezzo® 3.5 mg early zolpidem bioavailability vs Ambien®
Intermezzo® 3.5 mg delivered greater early zolpidem bioavailability than a ~3x higher Ambien® dose PK comparison study: Intermezzo® 3.5mg vs. Ambien 10mg PO n=33 Area under the curve (AUC) (ng.hr/mL) Intermezzo® 3.5 mg Ambien® 10 mg Time (min) 0 1 2 3 4 0 5 10 15 20 25 9.3x 2.9x 1.4x
Slide 11: Regulatory Review
Regulatory Review Transcept PHARMACEUTICALS, INC.
Slide 12: FDA Complete Response Letter: October 2009
FDA Complete Response Letter: October 2009 FDA indicated Transcept has submitted substantial evidence of effectiveness for the use of Intermezzo® in its intended indication FDA recognized that the Intermezzo® data did not indicate significant next-day residual effects at 4 hrs However, given the uni
Slide 13: Actions to address FDA Complete Response Letter
Actions to address FDA Complete Response Letter Inadvertent re-dosing in a single night FDA has indicated that redesigned unit dose packaging appears to reduce the potential for inadvertent re-dosing in a single night. Inadvertent dosing with < 4 hours bedtime remaining FDA has agreed to a highway d
Slide 14: Redesigned unit dose packaging for NDA resubmission
Redesigned unit dose packaging for NDA resubmission Prototype package: product is not approved by FDA Prototype package: product is not approved by FDA Prototype package only: Intermezzo® is not approved by the U.S. Food and Drug Administration.
Slide 15: Highway driving study overview
Highway driving study overview Approximately 40 healthy adult volunteers Highway driving over a one-hour period Single-center (Maastricht), double-blind, randomized, placebo-controlled crossover design Key comparisons: Intermezzo® 3.5mg vs. placebo, 4 hours post-dose Intermezzo® 3.5mg vs. placebo, 3
Slide 16: U.S. Commercial Partnership: Purdue Pharma
U.S. Commercial Partnership: Purdue Pharma
Slide 17: Purdue Pharma: Intermezzo® U.S. primary care marketing partner
Purdue Pharma: Intermezzo® U.S. primary care marketing partner > $2.5 billion 2009 revenue, leading pain therapeutic franchise, significant U.S. primary care marketing and sales presence Intermezzo®: an important new product opportunity for Purdue Purdue team actively engaged with Transcept to addre
Slide 18: Purdue Pharma agreement: key Transcept benefits
Purdue Pharma agreement: key Transcept benefits Purdue to commercialize Intermezzo® to U.S. primary care market Milestone payments Upfront license fee: $25M received August 2009 FDA approval milestone of $30M, reduced by $2M each 30-day period after June 30, 2010 Up to $90M additional upon the achie
Slide 19: Intermezzo®: Intellectual property
Intermezzo®: Intellectual property
Slide 20: Intermezzo®: two formulation patents issued; method of use patents pending
Intermezzo®: two formulation patents issued; method of use patents pending Formulation for transmucosal absorption Two issued U.S. patents - 7,682,628 and 7,658,945 Patents expire no sooner than February 2025 Low dose zolpidem, ~1mg to ~5mg Formulation with buffer system for transmucosal absorption
Slide 21: Pipeline development
Pipeline development Transcept PHARMACEUTICALS, INC.
Slide 22: TO-2061: ultra low dose ondansetron adjunctive therapy in OCD
TO-2061: ultra low dose ondansetron as adjunctive therapy in patients with obsessive compulsive disorder who have not adequately responded to SSRI treatment
Slide 23: Significant unmet medical need: OCD patients not responding to SSRI treatment
Significant unmet medical need: OCD patients not responding adequately to SSRI treatment (TR-OCD) Obsessive Compulsive Disorder Intrusive thoughts and repetitive actions to reduce distress Affects 1% to 2% of U.S. adult population, 40% to 50% seek treatment Significantly impacts everyday life activi
Slide 24: Pilot studies: ultra low dose adjunctive ondansetron therapy in TR-OCD
Pilot studies: ultra low dose adjunctive ondansetron therapy in TR-OCD Ondansetron (5-HT3 antagonist approved as Zofran®) Affects serotonin and dopamine pathways Typical daily Zofran® doses of 16 mg to 24 mg during chemotherapy Two 12 week open-label adjunctive therapy studies with ondansetron titra
Slide 25: Pilot studies: ultra low dose adjunctive ondansetron therapy in TR-OCD results
Pilot studies: ultra low dose adjunctive ondansetron therapy in TR-OCD Results OCD symptoms improved over baseline in patients who had responded poorly to SSRI monotherapy and SSRIs in combination with atypical antipsychotics In Pilot Study B, where relapse data were collected, most patients who res
Slide 26: 44% mean improvement (YBOCS) in responders to adjunctive ondansetron
44% mean improvement (YBOCS) in 12 of 21 patients who responded to adjunctive ondansetron therapy Pilot Study B, n=21 YBOCS% decrease from baseline (Mean ± SE) ALL PATIENTS 26.3% improvement at 12 weeks RESPONDERS (57% OF PATIENTS) 44% improvement at 12 weeks 0% 10% 20% 30% 40% 50% Week 2 Week 4 Wee
Slide 27: TO-2061: Development overview
TO-2061: Development overview Regulatory highlights IND accepted Q2 2010: opening PK study may proceed 505b2 NDA pathway PK studies: Planned for completion ~H1 2011 Double-blind, placebo-controlled study of SSRI adjunctive therapy with ultra low dose ondansetron in TR-OCD patients, n~150 If successf
Slide 28: Commercial strategy
Commercial strategy Intellectual property Method of use patent application filed, priority date May 19, 2009 Ondansetron, up to ~1.5 mg/day Pending claims for treating TR-OCD with ondansetron augmentation of SSRIs Managed markets: positive initial reception Managed care survey: 7 payer organizations
Slide 29: Financial Overview
Financial Overview Transcept
Slide 30: Financial position: March 31, 2010
Financial position: March 31, 2010 Cash & investments: $83.1 M Q1 2010 cash burn rate: $1.9 M / month Shares outstanding: 13.4 M Options / warrants / other: 2.5 Total: 15.9 M Employees: 31 Q2 2010 announcement scheduled for Monday, August 9, after market close
Slide 31: Key Transcept goals and activities
Key Transcept goals and activities Completed Intermezzo® US marketing partnership, July 09 Patent coverage: two Intermezzo® formulation patents issued Proposal to FDA on Intermezzo® NDA resubmission, Feb 10 FDA agreement on highway driving study design, March 10 Begin highway driving study, June 201
Slide 32: Transcept Pharmaceuticals, Inc.
Transcept Pharmaceuticals, Inc. Intermezzo® is a registered trademark of Transcept Pharmaceuticals, Inc. Ambien® is a registered trademark of sanofi-aventis Zofran® and Paxil® are registered trademarks of The GlaxoSmithKline Group of Companies Prozac® is a registered trademark of Eli Lilly & Co. Luv
Slide 33: Intermezzo® Phase Studies
Intermezzo® Phase 1 Studies Transcept PHARMACEUTICALS, INC.
Slide 34: Intermezzo®: mean DSST scores
Intermezzo®: mean DSST scores ( D from baseline) Phase 1 PK/PD Study n=24 DSST (Change from baseline +/- SE) Placebo Intermezzo® 1.75 mg Intermezzo® 3.5 mg Time (min) 6 4 2 0 -2 -4 -6 -8 -10 -12 -14 -16 0 20 60 90 120 150 180 240 300
Slide 35: 3.5 mg Intermezzo® vs. Ambien® plasma profile
3.5 mg Intermezzo® vs. 10 mg Ambien® plasma profile Intermezzo® 3.5mg vs. Ambien® 10mg PO after an overnight fasting, n=33 Mean plasma concentration (ng/ml) 140 120 100 80 60 40 20 0 0 1 2 3 4 5 6 7 8 Ambien® 10 mg Intermezzo 3.5 mg Time (hours)
Slide 36: Intermezzo® Sleep Lab Study
Intermezzo® Sleep Lab Study Transcept PHARMACEUTICALS, INC.
Slide 37: Objective Latency to Persistent Sleep following a middle of the night awakening
Intermezzo®: Objective Latency to Persistent Sleep following a middle of the night awakening Phase 3 Sleep Lab Study n = 82 Average Latency to Persistent Sleep (min) 50 40 30 20 10 0 p<0.001 vs. Placebo p<0.001 vs. Placebo 37.29 23.71 14.16 p<0.003 vs. Placebo p<0.001 vs. Placebo 44.64 30.66 16.97 A
Slide 38: Proportion of patients asleep following a middle of the night awakening
Intermezzo®: proportion of patients asleep following a middle of the night awakening Phase 3 Sleep Lab Study n = 82 75% 56% 28% % Patient Asleep 0 10 20 30 40 50 60 70 80 90 100 <10 <20 <30 Time (min) Placebo Intermezzo 3.5 mg Intermezzo 1.75 mg Baseline
Slide 39: Next-day residual effects of Intermezzo® vs. placebo
Next-day residual effects of Intermezzo® 1.75 mg and 3.5 mg vs. placebo Phase 3 Sleep Lab Study n = 82 p<0.62 vs. Placebo p<0.15 vs. Placebo DSST symbol matches per 90 seconds 70 60 50 40 30 20 10 0 61.88 61.59 60.57 Objective (DSST) p<0.44 vs. Placebo p<0.91 vs. Placebo Patient sedation rating: 0 t
Slide 40: Intermezzo®: Good or Excellent next day ratings
Intermezzo®: “Good” or “Excellent” next day ratings Phase 3 Sleep Lab Study n = 82 % of patients reporting good or excellent on a 4 point Likert Scale 50 40 30 20 10 0 NS p<0.001 vs. Placebo 42.6 32.9 23.5 p<0.017 vs. Placebo p<0.001 vs. Placebo 40.0 36.5 23.5 p<0.024 vs. Placebo p<0.009 vs. Placebo
Slide 41: Intermezzo® Outpatient Study
Intermezzo® Outpatient Study
Slide 42: Intermezzo®: Latency to Sleep Onset, week avg
Intermezzo®: Latency to Sleep Onset, 4 week avg Phase 3 outpatient study n = 294 Latency to Sleep Onset LS Mean (minutes) 80 70 60 50 40 30 20 10 0 69.42 56.37 Baseline 4 week treatment p<0.0001 vs. Placebo 68.13 38.22 Baseline 4 week treatment Baseline Placebo Intermezzo® 3.5mg
Slide 43: Intermezzo®: Latency to Sleep Onset, weekly
Intermezzo®: Latency to Sleep Onset, weekly Phase 3 outpatient study n = 294 LS Mean (minutes) 70 60 50 40 30 20 10 0 p<0.0001 vs. Placebo p<0.0001 vs. Placebo p<0.0001 vs. Placebo p<0.0001 vs. Placebo Baseline week 1 week 2 week 3 week 4 Placebo Intermezzo® 3.5mg
Slide 44: Next day sleepiness/alertness scores, week avg
Intermezzo®: next day sleepiness/alertness scores, 4 week avg Phase 3 outpatient study n = 294 ALERT MORE LS Mean—Sleepiness MORE SLEEPY 9 8 7 6 5 4 3 2 1 0 5.24 4.71 Baseline 4 week treatment p<0.0041 vs. Placebo 5.59 4.87 Baseline 4 week treatment Baseline Placebo Intermezzo® 3.5mg
Slide 45: Intermezzo®: average weekly treatment exposure
Intermezzo®: average weekly treatment exposure Phase 3 outpatient study n = 294 Number of tablets per week 5 4 3 2 1 0 Placebo wk 1 Placebo wk 2 week 1 week 2 week 3 week 4 Placebo Intermezzo® 3.5mg
Slide 46: Distribution of self-reported MOTN awakenings
Distribution of self-reported MOTN awakenings Phase 3 outpatient study n = 294 Number of MOTN Calls 1600 1400 1200 1000 800 600 400 200 0 8-9pm 9-10pm 10-11-pm 11-12am 12-1am 1-2am 2-3am 3-4am 4-5am 5-6am 6-7am MOTN treatment call to IVRS
Slide 47: Intermezzo® highway driving study
Intermezzo® highway driving study Study schematic
Slide 48: Intermezzo® highway driving study: study schematic
Intermezzo® highway driving study: study schematic Treatment Arms Bedtime dose MOTN dose (or) MOTN dose Wake-up time Drive time 11:15pm 4:15am 5:15am 7:30am 8:15am A1 zopiclone placebo x x A2 zopiclone placebo x x B1 placebo placebo x x B2 placebo placebo x x C placebo Intermezzo® x x D placebo Inte
Slide 49: TO-2061 Pilot Study B
TO-2061 Pilot Study B Transcept PHARMACEUTICALS, INC.
Slide 50: Responders relapsed within four weeks after ondansetron treatment ended
8 of 12 responders relapsed within four weeks after ondansetron treatment period ended Pilot Study B, n=21 Ondansetron augmentation phase After ondansetron treatment period ended 38.3% worsening from Week 12 Decrease = improvement Average YBOCS scores (Mean ± SE) 40 30 20 10 Week 0 Week 2 Week 4 Wee
Transcept Pharmaceuticals — Investor Presentation (August 2010) on 6ix